An autopsy case of pulmonary fissure induced by zygomycosis

Yuichiro Imai1
Yasushi Adachi2,3
Takashi Kimura4
Chikara Nakano2
Toshiki Shimizu4
Ming Shi2
Mitsuhiko Okigaki6
Tomohiko Shimo1
Kazunari Kaneko1
Susumu Ikehara2

1Department of Pediatrics, Kansai Medical University, Osaka, 2Department of Stem Cell Disorders, Kansai Medical University, Osaka, 3Division of Clinical Pathology, Toyooka Hospital, Hyogo, 4First Department of Internal Medicine, Kansai Medical University, Osaka, 5Second Department of Internal Medicine, Kansai Medical University, Osaka, 6Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Kyoto, Japan

Correspondence: Susumu Ikehara
Department of Stem Cell Disorders, Kansai Medical University, 10-15 Fumizoncho, Moriguchi City, Japan 570-8506
Tel +81 6 6992 1001 ext 2470
Fax +81 6 6994 8283
Email ikehara@takii.kmu.ac.jp

Abstract: For immunodeficient patients, fungi are life-threatening pathogens. In this paper, we present an autopsy case of combined zygomycosis and aspergillosis. A female in her 70s on chronic hemodialysis was admitted to a hospital suffering bloody sputum, dyspnea, and fever, probably due to perinuclear anti-neutrophil cytoplasmic antibody-related vasculitis. Antibiotics were administered and immunosuppressive therapy was started, resulting in an improvement in her condition. Pneumonia later developed, followed by pulmonary bleeding and intractable pneumothorax from which she ultimately died. On autopsy, the upper lobe of the left lung was found to have hemorrhagic necrosis and showed a large longitudinal fissure. Microscopically, Zygomycota were observed in both the lungs and heart, while Aspergillus was found in the middle lobe of the right lung. Zygomycosis, which usually has a poor prognosis, is assumed to have induced hemorrhagic infarction of the lungs, inducing pulmonary bleeding and necrosis, despite the use of lipid formulations of amphotericin B, which are effective medicines against Zygomycota.

Keywords: pulmonary fissure, zygomycosis, aspergillosis, lung, immunosuppression

Introduction
Fungi are responsible for life-threatening infections in patients with immunodeficiency.1 Common pathogens are Candida and Aspergillus.2 However, there has been an increase in the number of patients with zygomycosis. This is probably due to the increased use of immunosuppressive therapies and newly developed antifungal agents, which are effective against Candida and Aspergillus but not against Zygomycota. Thus, cases have been identified as being associated with leukemia,3 aplastic anemia,4 bone marrow transplantation,5 diabetes mellitus,6 renal disease,7 burns,7 and corticosteroid therapy.3,5 The most common clinical zygomycosis manifestations are rhino-orbital-cerebral, cutaneous, pulmonary, disseminated, and gastrointestinal.8 The most clinically important Zygomycota are those of the Mucorales order, which are widespread in nature. The likelihood of infection following ingestion or inhalation depends on the host's resistance mechanisms rather than on the number of infectious particles.8 Pulmonary zygomycosis has been reported in immunodeficient patients, with extremely poor prognosis.9

In this paper, we present an autopsy case of combined zygomycosis and aspergillosis associated with immunosuppressive therapy.

Case report
A female patient in her 70s on chronic hemodialysis due to chronic renal failure presented with bloody sputum, dyspnea, and fever. This was the first episode of these
symptoms she had experienced. As her condition worsened, she was admitted to hospital 3 days after the onset of the disease. She was diagnosed with pulmonary bleeding, probably due to perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA)-related vasculitis, as she was positive for p-ANCA (138 U/mL [normal < 9.0 U/mL]). Consolidation of the upper lobes in the bilateral lungs was found in her chest X-ray and computed tomography image (Figure 1). Cultures of sputum and blood were negative. Plasmapheresis, steroid pulse, and administration of azathioprine and antibiotics (meropenem, sulfamethoxazole/trimethoprim, and fluconazole) were carried out. Her dyspnea improved and C-reactive protein (CRP), which was 7.7 mg/dL on admission, gradually decreased to 2.2 mg/dL by 2 weeks following admission. Consolidation areas of the lungs also decreased (Figure 1).

Subsequently, the pulmonary bleeding reappeared and dyspnea developed, probably due to pneumonia. Pneumothorax occurred (Figure 1) and she needed mechanical ventilation. Three weeks after admission, she developed pneumonia (Figure 1) and the CRP titer increased again. Candida species were detected on blood culture at 21 days after admission. Micafungin was started, replacing the fluconazole. Twenty-five days after admission, levofloxacin and lipid formulations of amphotericin B (AMB) were also started.

However, her dyspnea continued to develop and she died 4 weeks following her admission. Beta-D-glucan was negative in her serum until 21 days after her admission, but increased to 35.2 pg/mL at 26 days after her admission. p-ANCA gradually decreased during her hospitalization until it finally reached the normal range 2 days before her death.

**Pathology report**

Four hours after her death, an autopsy was carried out. There were some purpuras on the skin.

**Macroscopic examination**

Both lungs were found to show congestion and edema; the weights of the left and right lung were 550 g and 640 g, respectively (Figure 2). Most of the upper lobe of the left lung displayed hemorrhagic necrosis and there was a 9 cm long longitudinal fissure in the lobe. Cavities were found in the middle lobe of the right lung. Bloody pleural effusion in bilateral thoracic cavities and thickening of pleura in the left lung were observed. There was no significant disorder in the heart. The weight of the left kidney was 15 g; this was assumed the result of hypoplasia. The weight of the right kidney was 48 g. The kidney cortex was thin – 1 mm in the left kidney and 2 mm in the right.

**Microscopic examination**

Massive bleeding in most alveoli and a large necrotic area were observed in the upper lobe of the left lung. Non-septate irregularly branched hyphae of Zygomycota existed in the bilateral lungs and heart (Figures 3 and 4). The hyphae were frequently observed around and within the blood vessels, causing obstruction and thromboembolization of blood vessels, which turned into hemorrhagic infarction.

![Figure 1](image.png) Changes in the chest X-rays and chest computed tomography (CT) images of the patient. Chest X-rays and CT images at hospitalization and at 15, 18, and 27 days after hospitalization are shown.
and necrosis of the adjacent tissue in the bilateral lung. In particular, in the upper lobe of the left lung, the hyphae existed not only around and within the blood vessels but also in the alveoli.

In the wall of the cavity in the middle lobe of the right lung, there were numerous basophilic septate hyphae with Y-shaped branching, suggesting that these hyphae were *Aspergillus* (Figure 4A and B). Zygomycota hyphae were observed around and within the blood vessels in the muscle layer of the left ventricle of the heart (Figure 4C and D). Many inflammatory cells had infiltrated the blood vessels, suggesting that the Zygomycota infection induced vasculitis, thrombosis, and fungal myocarditis. Caused by Zygomycota were observed in the left ventricle of the heart. Small necrotic areas of cardiac muscle were also observed. Glomerular sclerosis was observed in most of the glomeruli of both kidneys, suggesting that the kidneys were in the end stage. Chronic thyroiditis was also observed. We did not find any evidence of candidiasis.

**Discussion**

In this paper, we have presented an autopsy case of combined zygomycosis and aspergillosis in an immunodeficient patient that was caused by immunosuppressive therapy.

Although fungi are widespread in nature, lethal infection with fungi is very rare in healthy persons. However, infectious fungal diseases are sometimes lethal in those who are immunodeficient. Recently, a number of protocols to detect fungi have been developed. These include the detection of the specific sequence of fungal DNA, the detection of serum β-D-glucan, and enzyme-linked immunosorbent assays. However, although serum β-D-glucan increases in *Candida* or *Aspergillus* infections, it does not do so in Zygomycota. Enzyme-linked immunosorbent assays have also been developed for *Candida* and *Aspergillus* but not for Zygomycota. Therefore, it is very difficult to confirm Zygomycota infections.

Pharmaceutical agents for fungi have also been developed, including voriconazole, itraconazole, and so on. These medicines are easier to use than AMB due to the
lower incidence of side effects and are therefore used prophylactically during therapy for malignancies. Zygomycota are resistant to most antifungal agents that are active against invasive aspergillosis and are increasingly encountered as breakthrough infections in patients who are receiving antifungal agents active against Candida and Aspergillus species.\textsuperscript{13–15} Only AMB deoxycholate (including lipid formulations of AMB [LAMB]) and the newer triazole, posaconazole, are active against zygomycosis.\textsuperscript{16,17} It has also been reported that delayed administration of AMB significantly increases mortality in patients with zygomycosis.\textsuperscript{18} In our case, we also used LAMB. However, LAMB was started 10 days after emergence of the patient’s second dyspnea (25 days after her admission), which may have been too late to suppress the activity of the Zygomycota.

During the autopsy, hemorrhagic necrosis was seen to have developed in the left lung due to the infarction of the pulmonary blood vessels induced by Zygomycota. The left lung had become very fragile, allowing a fissure to be induced, followed by intractable pneumothorax. It has been reported that Zygomycota tend to invade the blood vessels then induce infarction;\textsuperscript{19} our case was in line with this report.

In our case, p-ANCA was positive in the serum of the patient at admission. However, we did not confirm the presence of any vasculitis except for that induced by the zygomycosis, and p-ANCA became negative 2 days before her death, suggesting that the p-ANCA-associated vasculitis had been successfully treated by plasmapheresis, steroid pulse, and azathioprine. Until 2 weeks after the patient’s admission, CRP had decreased and her condition had improved. Therefore, it was thought that the zygomycosis developed 2 weeks after her admission. It has been reported that hemodialysis is associated with immunodeficiency.\textsuperscript{20} In this case, the steroid therapy, azathioprine, and plasmapheresis may have decreased the serum level of p-ANCA and improved the vasculitis, but accelerated the immunodeficiency, which may have induced the fungal infection.

Conclusion
In this report, we have described a case of combined Zygomycota and Aspergillus infection in a dialysis patient treated with immunosuppressive therapy. As previously described,\textsuperscript{18} even LAMB is not enough to suppress the activity of Zygomycota in an immunodeficient patient.

Acknowledgments
The authors thank Mr J Lee, Mr K Okano, Mr H Hongo, Mr H Egawa (Department of Anatomical Pathology, Kansai Medical University), Mr Y Kinoshita, Mr K Ichibe (Surgical Pathology, Kansai Medical University – Takii Hospital), Mr H Kawakami, Ms H Ogaki, Mr K Nagaoka, Mr T Kuge (Department of Laboratory, Tyooka Hospital) for their expert technical assistance and also thank Mr Hilary Eastwick-Field and Ms K Ando (Department of Stem Cell Disorders, Kansai Medical University) for manuscript preparation.

Disclosure
The authors report no conflicts of interest in this work.

References

---

**International Journal of General Medicine**

**Publish your work in this journal**

The *International Journal of General Medicine* is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas.

*Submit your manuscript here:* [http://www.dovepress.com/international-journal-of-general-medicine-journal](http://www.dovepress.com/international-journal-of-general-medicine-journal)